shRNA Targeting Sav1 Gene for Cardiomyocyte Renewal (US20260109983A1)
Summary
Baylor College of Medicine has filed US Patent Application US20260109983A1, published April 23, 2026, covering methods and compositions for cardiomyocyte renewal using shRNA molecules targeting the Sav1 gene within the Hippo signaling pathway. The application names James F. Martin, Yuka Morikawa, Todd Ryan Heallen, and John P. Leach as inventors, with a filing date of October 31, 2025 and application number 19376011. CPC classifications include C12N 15/113, A61K 31/713, and related genetic therapy categories.
“In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 263 changes logged to date.
What changed
Baylor College of Medicine's USPTO patent application US20260109983A1 discloses novel shRNA sequences targeting the Sav1 gene and methods for using them to stimulate cardiomyocyte regeneration in individuals with cardiac repair needs. The application covers pharmaceutical compositions containing the disclosed shRNA molecules and their use in treating conditions requiring cardiomyocyte renewal.
For parties in the biotechnology and gene therapy sectors, this published application establishes priority date and disclosed claim scope for Hippo pathway-targeted cardiac regeneration therapies. Competitors developing similar shRNA-based or Sav1-inhibiting approaches should review the claim language for potential design-around considerations. Researchers and investors in cardiac cell therapy should monitor the prosecution history for issued claims that may define the intellectual property landscape in this therapeutic area.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HIPPO AND DYSTROPHIN COMPLEX SIGNALING IN CARDIOMYOCYTE RENEWAL
Application US20260109983A1 Kind: A1 Apr 23, 2026
Assignee
Baylor College of Medicine
Inventors
James F. Martin, Yuka Morikawa, Todd Ryan Heallen, John P. Leach
Abstract
Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.
CPC Classifications
C12N 15/113 A61K 31/713 C12N 7/00 C12N 15/86 C12N 2310/14 C12N 2310/531 C12N 2320/30 C12N 2740/15043 C12N 2750/14143
Filing Date
2025-10-31
Application No.
19376011
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.